Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant
Status:
Unknown status
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
The main objective of this study was to compare the drug compliance in patients after renal
transplantation under once or twice-daily tacrolimus-based immunosuppressive regimen.
The rationale for this study is to access the influence of once-daily prolonged-release
tacrolimus versus standard twice-daily tacrolimus on drug compliance in renal transplantation
recipients base on the assumption that once-daily dosing regimen may help to improve drug
compliance.